

In the Claims:

Please amend claim 1 as follows:

--1. **[Amended]** A compound of the formula:



where R^1 is $\text{CH}_3\text{-(CH}_2\text{)}_n\text{-X-}$; in which

X is $\text{-C(O)-NH-CH}_2\text{-C(O)-}$, $\text{-NHCH}_2\text{-C(O)-}$, $\text{-ONH-CH}_2\text{-C(O)-}$,
 $\text{-OCH}_2\text{-CH}_2\text{-C(O)-}$, -CH=CH-C(O)- , -C(O)- , or a covalent bond; and n is an
integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP

AVVVFVTRKNR QVCANPEKKW VREYINSLEMS (SEQ ID No. 2)

or a sequence which is a variant of said sequence, the variant

sequence having at least 40 % sequence homology with said sequence;

or a pharmaceutically acceptable salt thereof. --

Please amend claim 6 as follows:

--6. **[Amended]** The compound of claim 1, wherein n is 4 and X is



[Note to The Examiner: The amendment seeks to "raise" the presently subscripted bond designation ("--") appearing after the recited methylene group]

Please amend claim 7 by replacing the comma (" , ") at the end of the claim with a period (".").

Please amend claim 9 as follows:

--9. **[Amended]** A method of treating a disease state in [mammals] **a mammal** that is alleviated by treatment with a RANTES inhibitor, which method comprises

administering to a mammal in need of such a treatment, a therapeutically effective amount of a compound of the formula:

R^1 -RANTES (2-68)

where R^1 is $CH_3-(CH_2)_n-X-$; in which

X is $-C(O)-NH-CH_2-C(O)-$, $-NHCH_2-C(O)-$, $-ONH-CH_2-C(O)-$, $-OCH_2-CH_2-C(O)-$, $-CH=CH-C(O)-$, $-C(O)-$, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:

PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP

AVVFVTRKNR QVCANPEKKW VREYINSLEMS (SEQ ID No. 2)

or a sequence which is a variant of said sequence, the variant

sequence having at least 40 % sequence homology with said sequence;

or a pharmaceutically acceptable salt thereof. --

Please amend claim 13 as follows:

--13. **[Amended]** A pharmaceutical composition for administration to a mammal having a disease state in that is alleviated by treatment with a RANTES inhibitor, which comprises a therapeutically effective amount of a compound of the formula:

R^1 -RANTES (2-68)

where R^1 is $CH_3-(CH_2)_n-X-$; in which

X is $-C(O)-NH-CH_2-C(O)-$, $-NHCH_2-C(O)-$, $-ONH-CH_2-C(O)-$, $-OCH_2-CH_2-C(O)-$, $-CH=CH-C(O)-$, $-C(O)-$, or a covalent bond; and n is an integer of 4-8;

and in which RANTES (2-68) is a polypeptide having the sequence:


PYSSDT TPCCFAYIAR PLPRAHIKEY FYTSGKCSNP


AVVFVTRKNR QVCANPEKKW VREYINSLEMS (SEQ ID No. 2)


or a sequence which is a variant of said sequence, the variant
sequence having at least 40 % sequence homology with said sequence;


or a pharmaceutically acceptable salt thereof;

in admixture with one or more pharmaceutically acceptable excipients. --

OST
Please amend claim 14 as follows: 

- 14. [Amended] A compound of [claim 1] ~~any of claims 1-8~~ modified by the
grafting of one or more organic chain-like molecules. -- 

OST
Please add the following new claims: 

- 17. The compound of claim 15 wherein the modification is at the C-terminus. 

18. The pharmaceutical composition of claim 13, wherein N is 4 and X
is -C(O)-NH-CH₂-C(O)-.

19. The pharmaceutical composition of claim 13, wherein N is 5 and X
is -NHCH₂-C(O)-.

20. The pharmaceutical composition of claim 13, wherein N is 7 and X
is -C(O)-.

21. The pharmaceutical composition of claim 13, wherein N is 8 and X
is a covalent bond.

22. The pharmaceutical composition of claim 13, wherein N is 4 and X
is -ONH-CH₂-C(O)-.

23. The pharmaceutical composition of claim 13, wherein N is 5 and X is $-\text{CH}=\text{CH}-\text{C}(\text{O})-$.
24. The pharmaceutical composition of claim 13, wherein N is 4 and X is $-\text{OCH}_2-\text{CH}_2-\text{C}(\text{O})-$.
25. A pharmaceutical compound of any of claims 13 or 18-24 modified by the grafting of one or more organic chain-like molecules.
26. The pharmaceutical compound of claim 25 wherein said molecule is polyethylene glycol.
27. The pharmaceutical compound of claim 25 wherein the modification is at the C-terminus.
28. The pharmaceutical compound of claim 26 wherein the modification is at the C-terminus.

Remarks

I. Status

This application is a continuation of US Patent Application Serial No. 08/141,833, filed on August 28, 1998 (now pending), which application claims priority from Provisional Application No. 60/056,292 (filed September 3, 1997), Provisional Application No. 60/077,874 (filed March 13, 1998), and Provisional Application No. 60/090,834 (filed June 26, 1998). Claims 1-28 are pending.

Applicants have requested the replacement of the Sequence Listing that was originally filed for US Patent Application Serial No. 08/141,833, with the Sequence Listing filed during the prosecution of that application on March 3, 2000. No new matter has been added by this amendment. For the convenience of the Examiner, the replacement Sequence Listing is additionally provided as an Exhibit.